Publications of 2023
Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study.
The Lancet Regional Health – Europe. | Open Access Published: October 29, 2023DOI:https://doi.org/10.1016/j.lanepe.2023.100768
Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis.
Annals of the Rheumatic Diseases | 2023 Sep 1:ard-2023-224503. doi: 10.1136/ard-2023-224503. PMID: 37657927
Liposomal AntagomiR-155-5p restores anti-inflammatory macrophages and improves arthritis in pre-clinical models of Rheumatoid arthritis.
Arthritis Rheumatol | 2023 Aug 1. doi: 10.1002/art.42665. PMID: 37527031
Post-transcriptional checkpoints in autoimmunity
Nature Reviews Rheumatology | 2023 Aug;19(8):486-502. doi: 10.1038/s41584-023-00980-y. Epub 2023 Jun 13. PMID: 37311941 Review.
Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
JAMA Netw Open | 2023 Jul 3;6(7):e2323098. doi: 10.1001/jamanetworkopen.2023.23098. PMID: 37436748
Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma.
Haematologica | 2023 Mar 23. doi: 10.3324/haematol.2022.282214. Online ahead of print. PMID:36951162
Cancer screening in chronic inflammatory rheumatic diseases.
Joint Bone Spine | 2023 Feb 24:105557. doi: 10.1016/j.jbspin.2023.105557. Online ahead of print.PMID: 36842758
Amphiphilic Phosphorus Dendrons Associated with Anti-inflammatory siRNA Reduce Symptoms in Murine Collagen-Induced Arthritis.
Biomacromolecules | 2023 Feb 13;24(2):667-677. doi: 10.1021/acs.biomac.2c01117. Epub 2023 Jan 4.
Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors.
Ann Neurol. | 2023 Feb;93(2):257-270. doi: 10.1002/ana.26512. Epub 2022 Oct 17.PMID: 36151879 Free PMC article.
Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.
Eur J Cancer. | 2023 Jan;178:49-59. doi: 10.1016/j.ejca.2022.10.013. Epub 2022 Oct 27.PMID: 36403367
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors.
Eur J Cancer. | 2023 Jan;179:28-47. doi: 10.1016/j.ejca.2022.11.001. Epub 2022 Nov 12.PMID: 36473326
Publications of 2022
Using genetics to predict toxicity of cancer immunotherapy
Nature Medicine | volume 28, pages2471–2472 (2022)
Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity
Rheumatology | keac710, https://doi.org/10.1093/rheumatology/keac710
CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia
Nature Communications | doi: 10.1038/s41467-022-34548-3 - Article number: 6739 (2022) - 08 November 2022
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.
Cancer Treat Rev. | 2022 Nov;110:102452. doi: 10.1016/j.ctrv.2022.102452. Epub 2022 Aug 10.PMID: 35998515 Free article. Review.
Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report.
Front Immunol | 2022 Oct 24;13:920130. doi: 10.3389/fimmu.2022.920130. eCollection 2022. PMID: 36353627
Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study.
RMD Open | 2022 Oct;8(2):e002612. doi: 10.1136/rmdopen-2022-002612. PMID: 36270747
Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma.
Joint Bone Spine | 2022 Oct;89(5):105390. doi: 10.1016/j.jbspin.2022.105390. Epub 2022 Apr 28. PMID: 35490943
Immune-related adverse events of cancer immunotherapies targeting kinases.
Pharmacol Ther | 2022 Sep;237:108250. doi: 10.1016/j.pharmthera.2022.108250. Epub 2022 Jul 14. PMID: 35843306
Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts.
RMD Open | 2022 Aug;8(2):e002442. doi: 10.1136/rmdopen-2022-002442. PMID: 35999028
Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.
RMD Open | 2022 Jun;8(2):e002139. doi: 10.1136/rmdopen-2021-002139. PMID: 35738803
Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses.
RMD Open | 2022 May;8(1):e002308. doi: 10.1136/rmdopen-2022-002308. PMID: 35589332
Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases.
Arthritis Rheumatol | 2022 Jun;74(6):927-933. doi: 10.1002/art.42058. Epub 2022 Mar 29. PMID: 34962357
Features of non-Hodgkin's lymphoma diagnosed in minor salivary gland biopsies from primary Sjögren's syndrome patients.
Rheumatology (Oxford) | 2022 Aug 30;61(9):3818-3823. doi: 10.1093/rheumatology/keab949. PMID: 34940802
Interplay between mucus mobility and alveolar macrophage targeting of surface-modified liposomes.
J Control Release | 2022 Dec;352:15-24. doi: 10.1016/j.jconrel.2022.10.006. Epub 2022 Oct 14. PMID: 36209941
Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.
Br J Pharmacol | 2022 Sep;179(18):4534-4548. doi: 10.1111/bph.15898. Epub 2022 Jul 13. PMID:35726496
Improving dexamethasone drug loading and efficacy in treating arthritis through a lipophilic prodrug entrapped into PLGA-PEG nanoparticles.
Drug DelivTransl Res | 2022 May;12(5):1270-1284. doi: 10.1007/s13346-021-01112-3. Epub 2022 Jan 6. PMID:34993924Free PMC article
Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.
Respir Med Res. | 2022 Nov;82:100969. doi: 10.1016/j.resmer.2022.100969. Epub 2022 Nov 9.PMID: 36370683
Ocular Inflammation Induced by Immune Checkpoint Inhibitors.
J Clin Med. | 2022 Aug 25;11(17):4993. doi: 10.3390/jcm11174993.PMID: 36078923 Free PMC article.
[Toxicity of cancer immunotherapies: Traps to not miss, the role of the internist].
Rev Med Interne. | 2022 Aug;43(8):459-461. doi: 10.1016/j.revmed.2022.07.002. Epub 2022 Jul 22.PMID: 35879133 French. No abstract available.
Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma.
2022 Jun 14;14(12):2937. doi: 10.3390/cancers14122937.PMID: 35740604 Free PMC article. | Cancers (Basel).
Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective.
Crit Rev Immunol. | 2022;42(4):21-36. doi: 10.1615/CritRevImmunol.2023047272.PMID: 37022357 Review.
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.
Eur J Cancer. | 2022 Jan;160:134-139. doi: 10.1016/j.ejca.2021.10.018. Epub 2021 Nov 19.PMID: 34810048 Clinical Trial.
Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy.
Ann Rheum Dis. | 2022 Mar;81(3):e52. doi: 10.1136/annrheumdis-2020-217225. Epub 2020 Mar 18.PMID: 32188691 No abstract available.
Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database.
Ann Rheum Dis. | 2022 Feb;81(2):e32. doi: 10.1136/annrheumdis-2020-217018. Epub 2020 Feb 17.PMID: 32066555 Free article. No abstract available.
Publications of 2021
Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.
J Hematol Oncol | 2021 Oct 13;14(1):166. doi: 10.1186/s13045-021-01183-2. PMID: 34645504
Lymphoma complicating rheumatoid arthritis: results from a French case-control study.
RMD Open | 2021 Sep;7(3):e001698. doi: 10.1136/rmdopen-2021-001698. PMID: 34470830
Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice.
Clin Exp Immunol | 2021 Aug;205(2):169-181. doi: 10.1111/cei.13602. Epub 2021 May 30. PMID: 33864242
Main publications from the project leaders pertaining to the FHU CARE
Primary Sjögren's Syndrome.
N Engl J Med | 2018 Mar 8;378(10):931-939.
B cells in the pathogenesis of primary Sjögren syndrome.
Nat Rev Rheumatol | 2018 Mar;14(3):133-145.
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
JAMA Oncol | 2019 Jun 6. doi: 10.1001/jamaoncol.2019.1022.
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Science | 2015 Nov 27;350(6264):1079-84.
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Science | 2018 Jan 5;359(6371):91-97.
Previous Publications related to the research project (not necessarily by members of the FHU CARE)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
Ann Oncol | 2017 Jun 1;28(6):1368-1379
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment
Ann Rheum Dis | 2017 Oct;76(10):1747-1750.
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Ann Oncol | 2016 Apr;27(4):559-74.
Association of the autoimmune disease scleroderma with an immunologic response to cancer
Science | 2014 Jan 10;343(6167):152-7.